BioSpace News Archive

Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic’’ or the “Company”), announces today that Chief Executive Officer Donal Schmidt will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.

The clinical performance study, per U.S. Food & Drug Administration guidance, will being immediately at three (3) U.S.-based clinics.

Aimmune Therapeutics, Inc., today presented results from longitudinal analyses evaluating immunological outcomes of long-term daily oral immunotherapy (OIT) with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp].

HydroCision Inc., a medical device company that pioneered high velocity, heat-free, FluidJet™ technology for surgical resection, congratulates PROCEPT BioRobotics on the recent closing of its upsized initial public offering.

Today, the U.S. Food and Drug Administration is providing an update related to the June 14, 2021, recall of certain Philips Respironics ventilators, continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) machines.

Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results for the quarter ended September 30, 2021, and provided a business update.

Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, announced the appointment of Lyn Baranowski to its Board of Directors.

ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer and Ori Gon, Chief Financial Officer will present at H.C.WAINWRIGHT 7th annual Israel virtual conference held on November 15, 2021, the event is virtual and includes company presentation and 1-on-1 meetings.

REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II AAVIATE® trial and the ongoing Phase II ALTITUDE™ trial of RGX-314 using in-office suprachoroidal delivery for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME), respectively.

Acasti Pharma Inc., announced the annual grant of stock options to its employees, executives and directors.